(OTCBB:LPTN) Lpath, Inc

Turning Pennies into dollars:(OTCBB:LPTN) Lpath, Inc

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147

For more info: http://www.realpennies.com/otc/lptn

Lpath to Provide Fourth Quarter 2008 Business Review and 2009 Plan

(OTCBB:LPTN) Lpath, Inc.

Wednesday February 4, 12:44 pm ET

Webcast and Conference Call Set for Wednesday, February 11 at 11:30am EST

SAN DIEGO, CA-Feb 4, 2009 - Lpath, Inc. will host a teleconference on Wednesday, February 11 at 11:30am EST to provide a review of the fourth quarter 2008 and an outlook for 2009.

Lpath's chief executive officer, Scott Pancoast, will conduct the call. There will be a question-and-answer session directly following the presentation.

To participate in the teleconference, please call toll-free 877-407-9210 five minutes before the scheduled start in order to register for the call. The call is also accessible on the Internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=140640.

A replay of the call will be available three hours after the call's completion for seven days at 877-660-6853 . Account number 286 and conference ID number 312160 are both required for playback.

About Lpath

Lpath, Inc., headquartered in San Diego, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP, an antibody against Sphingosine-1-Phosphate , is currently in a Phase 1 clinical trial in cancer and also holds promise against multiple sclerosis and various other disorders. ASONEP is being developed with the support of partner Merck-Serono as part of a worldwide exclusive license. A second product candidate, iSONEP (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab, is an antibody against Lysophosphatidic Acid , a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2 drug-discovery engine, which the company is leveraging as a means to expand its pipeline. Please visit www.Lpath.com.

Contact:

Lpath, Inc. Scott R. Pancoast 678-0800 President & CEO spancoast@Lpath.com http://www.Lpath.com Lpath Investor Relations Redington, Inc. 926-1733 Thomas Redington info@redingtoninc.com Source: Lpath, Inc.

Profile for Lpath, Inc.

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutics that targets bioactive signaling lipids to treat human diseases. The company’s lead product includes ASONEP, which is in Phase I clinical trials, is a humanized monoclonal antibody against sphingosine-1-phosphate for the treatment of cancer and multiple sclerosis, as well as other angiogenic-related diseases and inflammatory-oriented indications. Its products also comprise iSONEP, the ocular formulation of Sonepcizumab for the treatment of age-related macular degeneration, retinopathy, and glaucoma; and Lpathomab, a monoclonal antibody against lysophosphatidic acid for the treatment... Detailed LPTN Company Description...

LAST $0.90 USD

Realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com